



## Scythian Biosciences Announces Details of 4-for-1 Stock Split

<https://globenewswire.com/news-release/2018/04/10/1468027/0/en/Scythian-Biosciences-Announces-Details-of-4-for-1-Stock-Split.html>

TORONTO, April 10, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "**Company**" or "**Scythian**") (TSXV:SCYB) (Frankfurt:**9SB**) (OTC – Nasdaq Intl:SCCYF) is pleased to announce details of the 4-for-1 stock split previously announced by the Company on March 12, 2018 (the "**Stock Split**"). Pursuant to the Stock Split, each shareholder of record as of the close of business on April 13, 2018 (the "**Record Date**") will receive three additional common shares of Scythian. Scythian's common shares are expected to begin trading ex-distribution on a split basis at the opening on April 12, 2018.

The Stock Split will increase the number of issued and outstanding common shares of the Company from 7,333,397 to 29,333,588.

Registered shareholders of Scythian as of the Record Date will be mailed new certificates or direct registration statements representing the additional common shares issued to them as a result of the Stock Split on or about April 17, 2018. Non-registered shareholders' brokerage accounts will be credited with the additional common shares to which they are entitled as a result of the Stock Split.

"With this stock split we are very pleased to be able to enhance the availability and liquidity of our shares to allow more participation in Scythian's growing accomplishments," said Scythian CEO, Jonathan Gilbert. "This is a reflection of our continuing growth, and our potential for further expansion worldwide."

### **About Scythian Biosciences Corp.**

Scythian is a research and development company committed to advancing prevention and treatment efforts for concussion and traumatic brain injury with its proprietary cannabinoid-based combination drug therapy.

Scythian's mission is to be the first accepted drug regimen for the treatment of concussion. Scythian is partnered with the University of Miami and its neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen. Through the Company's collaborative efforts with the university, Scythian has access to the university's extensive network of experts in the fields of traumatic brain injury and concussion. These connections provide Scythian with the ability to conduct its clinical studies at world-class facilities by widely recognized medical professionals.

Scythian has initiated its international expansion by launching additional cannabis-related activities across the globe. These significant endeavours complement the Company's research and development efforts to enhance the many medical applications of cannabis.

Scythian is evaluating several strategic initiatives and pursuing partnerships with local cultivators, pharmaceutical import and distribution entities and universities in North America, South America, the Caribbean and beyond. This comprehensive approach positions Scythian as a potential global frontrunner in the research and development of medical cannabis.

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

## **CONTACT INFORMATION**

Scythian Biosciences Corp.  
Jonathan Gilbert, CEO  
Phone: (212) 729-9208  
Email: [info@scythianbio.com](mailto:info@scythianbio.com)

For media inquiries, please contact:  
David Schull or Nic Johnson  
Russo Partners  
(858) 717-2310  
[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)  
[nic.johnson@russopartnersllc.com](mailto:nic.johnson@russopartnersllc.com)